Gain Therapeutics (GANX) Cash from Operations Growth (1y) (2021 - 2026)
Gain Therapeutics (GANX) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.22% |
| Mar 31, 2026 | -23.71% |
| Dec 31, 2025 | -33.69% |
| Sep 30, 2025 | 18.92% |
| Jun 30, 2025 | 11.42% |
| Mar 31, 2025 | -6.55% |
| Dec 31, 2024 | 38.97% |
| Sep 30, 2024 | -53.18% |
| Jun 30, 2024 | -14.64% |
| Mar 31, 2024 | 14.96% |
| Dec 31, 2023 | -44.97% |
| Sep 30, 2023 | -20.60% |
| Jun 30, 2023 | 0.59% |
| Mar 31, 2023 | -72.32% |
| Dec 31, 2022 | 5.83% |
| Sep 30, 2022 | -50.03% |
| Jun 30, 2022 | -57.01% |
| Mar 31, 2022 | 12.90% |
| Dec 31, 2021 | -216.95% |
| Sep 30, 2021 | -190.37% |